This popular circuit party drug might get FDA approval… but there’s a catch

(Photo: Shutterstock)

Experts at the Food and Drug Administration (FDA) are due to meet on June 4 to mull whether to approve ecstasy (MDMA) for the treatment of Post-Traumatic Stress Disorder (PTSD).

The move comes after a pharma company, Lykos Therapeutics, conducted two trials of the drug as a potential therapy aid.

PTSD is a mental health condition induced by living through a traumatic event. It can include many symptoms, including anxiety, difficulty sleeping, flashbacks and nightmares.

PTSD can be caused by one-off events, such as surviving an accident or violent crime, or from sustained abuse or trauma. A study last year concluded LGBTQ people are more likely to suffer from PTSD. It can be sometimes linked to the discrimination or harassment they experience.

Living

READ MORE OF THIS POST AT Queerty